Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2021 | Oct. 25, 2021 | |
Cover [Abstract] | ||
Entity Registrant Name | CONMED CORPORATION | |
Document Quarterly Report | true | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2021 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2021 | |
Entity File Number | 001-39218 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 16-0977505 | |
Entity Address, Address Line One | 11311 Concept Blvd | |
Entity Address, City or Town | Largo, | |
Entity Address, State or Province | FL | |
Entity Address, Postal Zip Code | 33773 | |
City Area Code | 727 | |
Local Phone Number | 392-6464 | |
Entity Central Index Key | 0000816956 | |
Title of 12(b) Security | Common Stock, $0.01 par value | |
Trading Symbol | CNMD | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Document Transition Report | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 29,247,120 | |
Amendment Flag | false |
Consolidated Condensed Statemen
Consolidated Condensed Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Statement of Comprehensive Income [Abstract] | ||||
Net sales | $ 248,827 | $ 237,835 | $ 736,665 | $ 609,631 |
Cost of sales | 106,521 | 104,137 | 324,485 | 284,845 |
Gross profit | 142,306 | 133,698 | 412,180 | 324,786 |
Selling and administrative expense | 104,736 | 94,380 | 307,476 | 274,721 |
Research and development expense | 10,859 | 9,936 | 32,203 | 28,756 |
Operating expenses | 115,595 | 104,316 | 339,679 | 303,477 |
Income from operations | 26,711 | 29,382 | 72,501 | 21,309 |
Interest expense | 8,145 | 11,943 | 27,917 | 32,938 |
Other expense | 1,127 | 89 | 1,127 | 266 |
Income (loss) before income taxes | 17,439 | 17,350 | 43,457 | (11,895) |
Provision for income taxes | 2,491 | 10,500 | 5,359 | 2,728 |
Net income (loss) | 14,948 | 6,850 | 38,098 | (14,623) |
Comprehensive income (loss) | $ 13,756 | $ 8,976 | $ 42,242 | $ (16,858) |
Per share data: | ||||
Basic (in dollars per share) | $ 0.51 | $ 0.24 | $ 1.31 | $ (0.51) |
Diluted (in dollars per share) | $ 0.47 | $ 0.23 | $ 1.19 | $ (0.51) |
Weighted average common shares: | ||||
Basic (shares) | 29,179 | 28,583 | 29,097 | 28,529 |
Diluted (shares) | 32,143 | 29,426 | 32,020 | 28,529 |
Consolidated Condensed Balance
Consolidated Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 31,511 | $ 27,356 |
Accounts receivable, net | 165,433 | 177,152 |
Inventories | 228,572 | 194,868 |
Prepaid expenses and other current assets | 17,889 | 17,278 |
Total current assets | 443,405 | 416,654 |
Property, plant and equipment, net | 109,181 | 111,407 |
Goodwill | 617,651 | 618,440 |
Other intangible assets, net | 478,861 | 501,537 |
Other assets | 104,994 | 103,635 |
Total assets | 1,754,092 | 1,751,673 |
Current liabilities: | ||
Current portion of long-term debt | 12,251 | 18,415 |
Accounts payable | 46,596 | 53,310 |
Accrued compensation and benefits | 54,632 | 50,171 |
Other current liabilities | 69,713 | 68,305 |
Total current liabilities | 183,192 | 190,201 |
Long-term debt | 703,335 | 735,221 |
Deferred income taxes | 58,940 | 57,875 |
Other long-term liabilities | 52,942 | 59,338 |
Total liabilities | 998,409 | 1,042,635 |
Commitments and contingencies | ||
Shareholders' equity: | ||
Preferred stock, par value $.01 per share; authorized 500,000 shares; none outstanding | 0 | 0 |
Common stock, par value $0.01 per share; 100,000,000 shares authorized; 31,299,194 shares issued in 2021 and 2020, respectively | 313 | 313 |
Paid-in capital | 394,810 | 382,628 |
Retained earnings | 478,035 | 457,417 |
Accumulated other comprehensive loss | (59,537) | (63,681) |
Less: 2,064,390 and 2,410,045 shares of common stock in treasury, at cost in 2021 and 2020, respectively | (57,938) | (67,639) |
Total shareholders’ equity | 755,683 | 709,038 |
Total liabilities and shareholders’ equity | $ 1,754,092 | $ 1,751,673 |
Consolidated Condensed Balanc_2
Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Sep. 30, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 500,000 | 500,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 31,299,194 | 31,299,194 |
Treasury stock, shares (in shares) | 2,064,390 | 2,410,045 |
Consolidated Condensed Statem_2
Consolidated Condensed Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands | Total | Common Stock | Paid-in Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock |
Balance at period start (shares) at Dec. 31, 2019 | 31,299 | |||||
Balance at period start at Dec. 31, 2019 | $ 710,467 | $ 313 | $ 379,324 | $ 470,844 | $ (59,277) | $ (80,737) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Common stock issued under employee plans | (5,040) | (7,736) | 2,696 | |||
Stock-based compensation | 3,032 | 3,032 | ||||
Dividends on common stock ($0.20 per share) | (5,703) | (5,703) | ||||
Comprehensive income (loss): | ||||||
Cash flow hedging gain (loss), net | 2,405 | |||||
Pension liability, net of income tax | 535 | |||||
Foreign currency translation adjustments | (9,988) | |||||
Net income (loss) | 5,927 | |||||
Comprehensive income (loss) | (1,121) | |||||
Balance at period end (shares) at Mar. 31, 2020 | 31,299 | |||||
Balance at period end at Mar. 31, 2020 | 701,635 | $ 313 | 374,620 | 471,068 | (66,325) | (78,041) |
Balance at period start (shares) at Dec. 31, 2019 | 31,299 | |||||
Balance at period start at Dec. 31, 2019 | 710,467 | $ 313 | 379,324 | 470,844 | (59,277) | (80,737) |
Comprehensive income (loss): | ||||||
Cash flow hedging gain (loss), net | (3,050) | |||||
Pension liability, net of income tax | 1,605 | |||||
Foreign currency translation adjustments | (790) | |||||
Net income (loss) | (14,623) | |||||
Comprehensive income (loss) | (16,858) | |||||
Balance at period end (shares) at Sep. 30, 2020 | 31,299 | |||||
Balance at period end at Sep. 30, 2020 | 683,141 | $ 313 | 381,119 | 439,086 | (61,512) | (75,865) |
Balance at period start (shares) at Mar. 31, 2020 | 31,299 | |||||
Balance at period start at Mar. 31, 2020 | 701,635 | $ 313 | 374,620 | 471,068 | (66,325) | (78,041) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Common stock issued under employee plans | 133 | (1,150) | 1,283 | |||
Stock-based compensation | 3,555 | 3,555 | ||||
Dividends on common stock ($0.20 per share) | (5,712) | (5,712) | ||||
Comprehensive income (loss): | ||||||
Cash flow hedging gain (loss), net | (2,429) | |||||
Pension liability, net of income tax | 535 | |||||
Foreign currency translation adjustments | 4,581 | |||||
Net income (loss) | (27,400) | |||||
Comprehensive income (loss) | (24,713) | |||||
Balance at period end (shares) at Jun. 30, 2020 | 31,299 | |||||
Balance at period end at Jun. 30, 2020 | 674,898 | $ 313 | 377,025 | 437,956 | (63,638) | (76,758) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Common stock issued under employee plans | 1,455 | 562 | 893 | |||
Stock-based compensation | 3,532 | 3,532 | ||||
Dividends on common stock ($0.20 per share) | (5,720) | (5,720) | ||||
Comprehensive income (loss): | ||||||
Cash flow hedging gain (loss), net | (3,026) | (3,026) | ||||
Pension liability, net of income tax | 535 | 535 | ||||
Foreign currency translation adjustments | 4,617 | 4,617 | ||||
Net income (loss) | 6,850 | 6,850 | ||||
Comprehensive income (loss) | 8,976 | |||||
Balance at period end (shares) at Sep. 30, 2020 | 31,299 | |||||
Balance at period end at Sep. 30, 2020 | 683,141 | $ 313 | 381,119 | 439,086 | (61,512) | (75,865) |
Balance at period start (shares) at Dec. 31, 2020 | 31,299 | |||||
Balance at period start at Dec. 31, 2020 | 709,038 | $ 313 | 382,628 | 457,417 | (63,681) | (67,639) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Common stock issued under employee plans | 8,215 | 2,944 | 5,271 | |||
Stock-based compensation | 3,387 | 3,387 | ||||
Dividends on common stock ($0.20 per share) | (5,813) | (5,813) | ||||
Comprehensive income (loss): | ||||||
Cash flow hedging gain (loss), net | 3,926 | |||||
Pension liability, net of income tax | 631 | |||||
Foreign currency translation adjustments | (3,674) | |||||
Net income (loss) | 9,860 | |||||
Comprehensive income (loss) | 10,743 | |||||
Balance at period end (shares) at Mar. 31, 2021 | 31,299 | |||||
Balance at period end at Mar. 31, 2021 | 725,570 | $ 313 | 388,959 | 461,464 | (62,798) | (62,368) |
Balance at period start (shares) at Dec. 31, 2020 | 31,299 | |||||
Balance at period start at Dec. 31, 2020 | 709,038 | $ 313 | 382,628 | 457,417 | (63,681) | (67,639) |
Comprehensive income (loss): | ||||||
Cash flow hedging gain (loss), net | 8,064 | |||||
Pension liability, net of income tax | 1,893 | |||||
Foreign currency translation adjustments | (5,813) | |||||
Net income (loss) | 38,098 | |||||
Comprehensive income (loss) | 42,242 | |||||
Balance at period end (shares) at Sep. 30, 2021 | 31,299 | |||||
Balance at period end at Sep. 30, 2021 | 755,683 | $ 313 | 394,810 | 478,035 | (59,537) | (57,938) |
Balance at period start (shares) at Mar. 31, 2021 | 31,299 | |||||
Balance at period start at Mar. 31, 2021 | 725,570 | $ 313 | 388,959 | 461,464 | (62,798) | (62,368) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Common stock issued under employee plans | 2,726 | 414 | 2,312 | |||
Stock-based compensation | 4,290 | 4,290 | ||||
Dividends on common stock ($0.20 per share) | (5,830) | (5,830) | ||||
Comprehensive income (loss): | ||||||
Cash flow hedging gain (loss), net | 1,221 | |||||
Pension liability, net of income tax | 631 | |||||
Foreign currency translation adjustments | 2,601 | |||||
Net income (loss) | 13,290 | |||||
Comprehensive income (loss) | 17,743 | |||||
Balance at period end (shares) at Jun. 30, 2021 | 31,299 | |||||
Balance at period end at Jun. 30, 2021 | 744,499 | $ 313 | 393,663 | 468,924 | (58,345) | (60,056) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Common stock issued under employee plans | (1,062) | (3,180) | 2,118 | |||
Stock-based compensation | 4,327 | 4,327 | ||||
Dividends on common stock ($0.20 per share) | (5,837) | (5,837) | ||||
Comprehensive income (loss): | ||||||
Cash flow hedging gain (loss), net | 2,917 | 2,917 | ||||
Pension liability, net of income tax | 631 | 631 | ||||
Foreign currency translation adjustments | (4,740) | (4,740) | ||||
Net income (loss) | 14,948 | 14,948 | ||||
Comprehensive income (loss) | 13,756 | |||||
Balance at period end (shares) at Sep. 30, 2021 | 31,299 | |||||
Balance at period end at Sep. 30, 2021 | $ 755,683 | $ 313 | $ 394,810 | $ 478,035 | $ (59,537) | $ (57,938) |
Consolidated Condensed Statem_3
Consolidated Condensed Statements of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares | 3 Months Ended | |||||
Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | |
Dividends per share of common stock (in dollars per share) | $ 0.20 | $ 0.20 | $ 0.20 | $ 0.20 | $ 0.20 | $ 0.20 |
Consolidated Condensed Statem_4
Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Cash flows from operating activities: | ||
Net income (loss) | $ 38,098 | $ (14,623) |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
Depreciation | 12,519 | 13,617 |
Amortization of debt discount | 7,611 | 7,239 |
Amortization of deferred debt issuance costs | 2,946 | 2,697 |
Amortization | 40,747 | 40,973 |
Stock-based compensation | 12,003 | 10,119 |
Deferred income taxes | (1,311) | (786) |
Loss on early extinguishment of debt | 899 | 0 |
Increase (decrease) in cash flows from changes in assets and liabilities: | ||
Accounts receivable | 9,890 | 21,574 |
Inventories | (34,679) | (19,396) |
Accounts payable | (6,223) | 1,477 |
Accrued compensation and benefits | 5,030 | (8,864) |
Other assets | (15,915) | (6,013) |
Other liabilities | 6,370 | (3,628) |
Net cash provided by operating activities | 77,985 | 44,386 |
Cash flows from investing activities: | ||
Proceeds from sale of a facility | 0 | 3,227 |
Purchases of property, plant and equipment | (11,678) | (9,864) |
Payments related to business and asset acquisitions, net of cash acquired | 0 | (3,852) |
Net cash used in investing activities | (11,678) | (10,489) |
Cash flows from financing activities: | ||
Payments on term loan | (63,673) | (9,938) |
Proceeds from term loan | 52,411 | 0 |
Payments on revolving line of credit | (272,753) | (142,000) |
Proceeds from revolving line of credit | 236,753 | 152,000 |
Payments for Contingent Consideration | (3,536) | (2,071) |
Payments related to debt issuance costs | (2,000) | (2,057) |
Dividends paid on common stock | (17,418) | (17,099) |
Other, net | 9,457 | (3,730) |
Net cash used in financing activities | (60,759) | (24,895) |
Effect of exchange rate changes on cash and cash equivalents | (1,393) | 740 |
Net increase in cash and cash equivalents | 4,155 | 9,742 |
Cash and cash equivalents at beginning of period | 27,356 | 25,856 |
Cash and cash equivalents at end of period | 31,511 | 35,598 |
Non-cash investing and financing activities: | ||
Dividends payable | $ 5,837 | $ 5,720 |
Operations
Operations | 9 Months Ended |
Sep. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Operations | OperationsCONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. |
Interim Financial Information
Interim Financial Information | 9 Months Ended |
Sep. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Interim Financial Information | Interim Financial Information The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements. The information herein reflects all normal recurring material adjustments, which are, in the opinion of management, necessary to fairly present the results for the periods presented. The consolidated condensed financial statements herein consist of all wholly-owned domestic and foreign subsidiaries with all significant intercompany transactions eliminated. Results for the period ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The consolidated condensed financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K. Use of Estimates Preparation of the consolidated condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the reported amounts of revenue and expenses during the reporting period. Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. We are not aware of any specific event or circumstance that would require an update to our estimates or judgments or a revision of the carrying value of our assets or liabilities as of October 28, 2021, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. |
Revenues
Revenues | 9 Months Ended |
Sep. 30, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Revenues | Revenues The following tables present revenue disaggregated by primary geographic market where the products are sold, by product line and timing of revenue recognition: Three Months Ended Three Months Ended September 30, 2021 September 30, 2020 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 37,957 $ 98,444 $ 136,401 $ 38,913 $ 95,292 $ 134,205 Europe, Middle East & Africa 24,155 19,905 44,060 23,104 17,584 40,688 Asia Pacific 27,517 16,113 43,630 26,403 15,405 41,808 Americas (excluding the United States) 16,122 8,614 24,736 13,767 7,367 21,134 Total sales from contracts with customers $ 105,751 $ 143,076 $ 248,827 $ 102,187 $ 135,648 $ 237,835 Timing of Revenue Recognition Goods transferred at a point in time $ 96,389 $ 141,798 $ 238,187 $ 93,000 $ 134,745 $ 227,745 Services transferred over time 9,362 1,278 10,640 9,187 903 10,090 Total sales from contracts with customers $ 105,751 $ 143,076 $ 248,827 $ 102,187 $ 135,648 $ 237,835 Nine Months Ended Nine Months Ended September 30, 2021 September 30, 2020 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 115,864 $ 288,069 $ 403,933 $ 97,339 $ 243,137 $ 340,476 Europe, Middle East & Africa 77,327 58,594 135,921 62,726 50,345 113,071 Asia Pacific 80,403 44,911 125,314 66,737 34,211 100,948 Americas (excluding the United States) 47,215 24,282 71,497 35,152 19,984 55,136 Total sales from contracts with customers $ 320,809 $ 415,856 $ 736,665 $ 261,954 $ 347,677 $ 609,631 Timing of Revenue Recognition Goods transferred at a point in time $ 291,728 $ 412,298 $ 704,026 $ 237,224 $ 345,068 $ 582,292 Services transferred over time 29,081 3,558 32,639 24,730 2,609 27,339 Total sales from contracts with customers $ 320,809 $ 415,856 $ 736,665 $ 261,954 $ 347,677 $ 609,631 Contract liability balances related to the sale of extended warranties to customers are as follows: September 30, 2021 December 31, 2020 Contract liability $ 15,833 $ 13,666 Revenue recognized during the nine months ended September 30, 2021 and September 30, 2020 from amounts included in contract liabilities at the beginning of the period were $8.4 million and $7.6 million, respectively. There were no material contract assets as of September 30, 2021 and December 31, 2020. |
Comprehensive Income (Loss)
Comprehensive Income (Loss) | 9 Months Ended |
Sep. 30, 2021 | |
Equity [Abstract] | |
Comprehensive Income (Loss) | Comprehensive Income (Loss) Comprehensive income (loss) consists of the following: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net income (loss) $ 14,948 $ 6,850 $ 38,098 $ (14,623) Other comprehensive income (loss): Cash flow hedging gain (loss), net of income tax (income tax expense (benefit) of $929 and $(964) for the three months ended September 30, 2021 and 2020, respectively, and $2,568 and $(972) for the nine months ended September 30, 2021 and 2020, respectively) 2,917 (3,026) 8,064 (3,050) Pension liability, net of income tax (income tax expense of $201 and $170 for the three months ended September 30, 2021 and 2020, respectively, and $603 and $510 for the nine months ended September 30, 2021 and 2020, respectively) 631 535 1,893 1,605 Foreign currency translation adjustment (4,740) 4,617 (5,813) (790) Comprehensive income (loss) $ 13,756 $ 8,976 $ 42,242 $ (16,858) Accumulated other comprehensive loss consists of the following: Cash Flow Pension Cumulative Accumulated Balance, December 31, 2020 $ (5,945) $ (36,620) $ (21,116) $ (63,681) Other comprehensive income (loss) before reclassifications, net of tax 5,141 — (5,813) (672) Amounts reclassified from accumulated other comprehensive income (loss) before tax a 3,854 2,496 — 6,350 Income tax (931) (603) — (1,534) Net current-period other comprehensive income (loss) 8,064 1,893 (5,813) 4,144 Balance, September 30, 2021 $ 2,119 $ (34,727) $ (26,929) $ (59,537) Cash Flow Pension Cumulative Accumulated Balance, December 31, 2019 $ 493 $ (31,691) $ (28,079) $ (59,277) Other comprehensive income (loss) before reclassifications, net of tax (1,916) — (790) (2,706) Amounts reclassified from accumulated other comprehensive income (loss) before tax a (1,496) 2,115 — 619 Income tax 362 (510) — (148) Net current-period other comprehensive income (loss) (3,050) 1,605 (790) (2,235) Balance, September 30, 2020 $ (2,557) $ (30,086) $ (28,869) $ (61,512) (a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 5 and Note 11, respectively, for further details. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 9 Months Ended |
Sep. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments We enter into derivative instruments for risk management purposes only. We operate internationally and, in the normal course of business, are exposed to fluctuations in interest rates, foreign exchange rates and commodity prices. These fluctuations can increase the costs of financing, investing and operating the business. We use forward contracts, a type of derivative instrument, to manage certain foreign currency exposures. By nature, all financial instruments involve market and credit risks. We enter into forward contracts with major investment grade financial institutions and have policies to monitor the credit risk of those counterparties. While there can be no assurance, we do not anticipate any material non-performance by any of these counterparties. Foreign Currency Forward Contracts. We hedge forecasted intercompany sales denominated in foreign currencies through the use of forward contracts. We account for these forward contracts as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are included in accumulated other comprehensive loss. These changes in fair value will be recognized into earnings as a component of sales or cost of sales when the forecasted transaction occurs. We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency transaction exposures on intercompany receivables designated in foreign currencies. These forward contracts settle each month at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and have not applied hedge accounting to them. The following table presents the notional contract amounts for forward contracts outstanding: As of FASB ASC Topic 815 Designation September 30, 2021 December 31, 2020 Forward exchange contracts Cash flow hedge $ 178,908 $ 154,504 Forward exchange contracts Non-designated 37,254 42,380 The remaining time to maturity as of September 30, 2021 is within two years for hedge designated foreign exchange contracts and approximately one month for non-hedge designated forward exchange contracts. Statement of comprehensive income (loss) presentation Derivatives designated as cash flow hedges Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) ("AOCI") and net earnings on our consolidated condensed statements of comprehensive income (loss) and our consolidated condensed balance sheets: Amount of Gain (Loss) Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Three Months Ended September 30, Total Amount of Line Item Presented Derivative Instrument 2021 2020 Location of amount reclassified 2021 2020 2021 2020 Foreign exchange contracts $ 3,188 $ (3,542) Net Sales $ 248,827 $ 237,835 $ (1,077) $ 663 Cost of Sales 106,521 104,137 419 (215) Pre-tax gain (loss) $ 3,188 $ (3,542) $ (658) $ 448 Tax expense (benefit) 770 (856) (159) 108 Net gain (loss) $ 2,418 $ (2,686) $ (499) $ 340 Amount of Gain (Loss) Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Nine Months Ended September 30, Total Amount of Line Item Presented Derivative Instrument 2021 2020 Location of amount reclassified 2021 2020 2021 2020 Foreign exchange contracts $ 6,778 $ (2,526) Net Sales $ 736,665 $ 609,631 $ (4,948) $ 2,206 Cost of Sales 324,485 284,845 1,094 (710) Pre-tax gain (loss) $ 6,778 $ (2,526) $ (3,854) $ 1,496 Tax expense (benefit) 1,637 (610) (931) 362 Net gain (loss) $ 5,141 $ (1,916) $ (2,923) $ 1,134 At September 30, 2021, $1.5 million of net unrealized gains on forward contracts accounted for as cash flow hedges, and included in accumulated other comprehensive loss, are expected to be recognized in earnings in the next twelve months. Derivatives not designated as cash flow hedges Net losses from derivative instruments not accounted for as hedges and gains and losses on our intercompany receivables on our consolidated condensed statements of comprehensive income (loss) were: Three Months Ended September 30, Nine Months Ended September 30, Derivative Instrument Location on Consolidated Condensed Statements of Comprehensive Income (Loss) 2021 2020 2021 2020 Net loss on currency forward contracts Selling and administrative expense $ (48) $ (682) $ (398) $ (1,224) Net gain (loss) on currency transaction exposures Selling and administrative expense $ (441) $ 312 $ (1,320) $ 143 Balance sheet presentation We record these forward foreign exchange contracts at fair value. The following tables summarize the fair value for forward foreign exchange contracts outstanding at September 30, 2021 and December 31, 2020: September 30, 2021 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Prepaid expenses and other current assets $ 3,319 $ (1,311) $ 2,008 Foreign exchange contracts Other long-term assets 932 (145) 787 $ 4,251 $ (1,456) $ 2,795 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 21 (160) (139) Total derivatives $ 4,272 $ (1,616) $ 2,656 December 31, 2020 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Other current liabilities $ 1,500 $ (8,826) $ (7,326) Foreign exchange contracts Other long-term liabilities 23 (535) (512) $ 1,523 $ (9,361) $ (7,838) Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 25 (150) (125) Total derivatives $ 1,548 $ (9,511) $ (7,963) Our forward foreign exchange contracts are subject to a master netting agreement and qualify for netting in the consolidated condensed balance sheets. Fair Value Disclosure. FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. This guidance applies when fair value measurements are required or permitted. The guidance indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is defined based upon an exit price model. Valuation Hierarchy. A valuation hierarchy was established for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from or corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. There have been no significant changes in the assumptions. Valuation Techniques. Assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2021 consist of forward foreign exchange contracts. The Company values its forward foreign exchange contracts using quoted prices for similar assets. The most significant assumption is quoted currency rates. The value of the forward foreign exchange contract assets and liabilities were valued using Level 2 inputs and are listed in the table above. |
Inventories
Inventories | 9 Months Ended |
Sep. 30, 2021 | |
Inventory Disclosure [Abstract] | |
Inventories | Inventories Inventories consist of the following: September 30, December 31, Raw materials $ 76,637 $ 71,807 Work-in-process 17,658 15,864 Finished goods 134,277 107,197 Total $ 228,572 $ 194,868 |
Earnings (Loss) Per Share
Earnings (Loss) Per Share | 9 Months Ended |
Sep. 30, 2021 | |
Earnings Per Share [Abstract] | |
Earnings (Loss) Per Share | Earnings (Loss) Per ShareBasic earnings (loss) per share (“basic EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding resulting from employee stock options, restricted stock units, performance share units and stock appreciation rights ("SARs") as well as the Notes and related hedge transactions during the period. The following table sets forth the computation of basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net income (loss) $ 14,948 $ 6,850 $ 38,098 $ (14,623) Basic – weighted average shares outstanding 29,179 28,583 29,097 28,529 Effect of dilutive potential securities 2,964 843 2,923 — Diluted – weighted average shares outstanding 32,143 29,426 32,020 28,529 Net income (loss) (per share) Basic $ 0.51 $ 0.24 $ 1.31 $ (0.51) Diluted 0.47 0.23 1.19 (0.51) The shares used in the calculation of diluted EPS exclude options and SARs to purchase shares where the exercise price was greater than the average market price of common shares for the period and the effect of the inclusion would be anti-dilutive. Such shares aggregated approximately 0.7 million and 0.5 million for the three and nine months ended September 30, 2021, respectively, and 1.6 million for the three months ended September 30, 2020. As the Company was in a net loss position for the nine months ended September 30, 2020, there were no anti-dilutive shares. Our 2.625% convertible notes due in 2024 (the “Notes”) are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The following is intended to describe the impact of the Notes and related hedge transactions on the calculation of diluted EPS. Additional shares to be issued pursuant to the terms of the Notes and related hedge transactions, if any, would occur at maturity. The calculation of diluted EPS includes potential diluted shares upon conversion of the Notes when the average market price per share of our common stock for the period is greater than the conversion price of the Notes of $88.80. We intend to settle in cash the principal outstanding and use the treasury stock method when calculating their potential dilutive effect, if any. During the three and nine months ended September 30, 2021, our average share price exceeded the conversion price of the Notes and we included in our diluted share count 1.2 million shares, for both periods, assumed to be issued if the Notes were converted. During the three and nine months ended September 30, 2020, our average share price had not exceeded the conversion price of the Notes; therefore, under the net share settlement method, there were no potential shares issuable under the Notes to be used in the calculation of diluted EPS. We previously entered into convertible notes hedge transactions to increase the effective conversion price of the Notes to $114.92. However, our convertible notes hedges are not included when calculating potential dilutive shares since their effect is always anti-dilutive. Concurrently with entering into the hedge transactions, we also previously entered into warrant transactions under which we agreed to sell shares of our common stock at $114.92. The calculation of diluted EPS also includes |
Goodwill and Other Intangible A
Goodwill and Other Intangible Assets | 9 Months Ended |
Sep. 30, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets The changes in the net carrying amount of goodwill for the nine months ended September 30, 2021 are as follows: Balance as of December 31, 2020 $ 618,440 Foreign currency translation (789) Balance as of September 30, 2021 $ 617,651 Assets and liabilities of acquired businesses are recorded at their estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. Other intangible assets consist of the following: September 30, 2021 December 31, 2020 Weighted Average Amortization Period (Years) Gross Accumulated Gross Accumulated Intangible assets with definite lives: 22 Customer and distributor relationships 24 $ 342,501 $ (148,330) $ 342,639 $ (134,555) Sales representation, marketing and promotional rights 25 149,376 (58,500) 149,376 (54,000) Developed technology 16 106,604 (24,801) 106,604 (19,705) Patents and other intangible assets 16 75,836 (50,369) 73,516 (48,882) Intangible assets with indefinite lives: Trademarks and tradenames 86,544 — 86,544 — $ 760,861 $ (282,000) $ 758,679 $ (257,142) Customer and distributor relationships, trademarks and tradenames, developed technology and patents and other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. Sales representation, marketing and promotional rights represent intangible assets created under our agreement with Musculoskeletal Transplant Foundation (“MTF”). Amortization expense related to intangible assets which are subject to amortization totaled $8.3 million and $8.6 million in the three months ended September 30, 2021 and 2020, respectively, and $24.9 million and $25.6 million in the nine months ended September 30, 2021 and 2020, respectively, and is included as a reduction of revenue (for amortization related to our sales representation, marketing and promotional rights) and in selling and administrative expense (for all other intangible assets) in the consolidated condensed statements of comprehensive income (loss). Included in developed technology is $3.5 million of earn-out consideration that was paid during the third quarter of 2021 and an additional accrual of $2.4 million of earn-out consideration that is considered probable as of September 30, 2021 associated with a prior asset acquisition. This is recorded in other current liabilities at September 30, 2021. The estimated intangible asset amortization expense remaining for the year ending December 31, 2021 and for each of the five succeeding years is as follows: Amortization included in expense Amortization recorded as a reduction of revenue Total Remaining, 2021 $ 7,187 $ 1,500 $ 8,687 2022 26,554 6,000 32,554 2023 25,679 6,000 31,679 2024 24,929 6,000 30,929 2025 25,145 6,000 31,145 2026 24,652 6,000 30,652 |
Long Term Debt
Long Term Debt | 9 Months Ended |
Sep. 30, 2021 | |
Debt Disclosure [Abstract] | |
Long-term Debt | Long-Term Debt Long-term debt consists of the following: September 30, 2021 December 31, 2020 Revolving line of credit $ 171,000 $ 207,000 Term loan, net of deferred debt issuance costs of $1,448 and $1,668 in 2021 and 2020, respectively 229,102 240,145 2.625% convertible notes, net of deferred debt issuance costs of $4,144 and $5,475 in 2021 and 2020, respectively, and unamortized discount of $26,009 and $33,620 in 2021 and 2020, respectively 314,846 305,904 Financing leases 638 587 Total debt 715,586 753,636 Less: Current portion 12,251 18,415 Total long-term debt $ 703,335 $ 735,221 On July 16, 2021, we entered into a seventh amended and restated senior credit agreement consisting of: (a) a $233.5 million term loan facility and (b) a $585.0 million revolving credit facility. The revolving credit facility will terminate and the loans outstanding under the term loan facility will expire on July 16, 2026. The term loan is payable in quarterly installments increasing over the term of the facility. Proceeds from the term loan facility and borrowings under the revolving credit facility were used to repay the then existing senior credit agreement. Interest rates are at LIBOR (subject to 0.125% floor) plus an interest rate margin of 1.50% (1.625% at September 30, 2021). For borrowings where we elect to use the alternate base rate, the initial base rate is the greatest of (i) the Prime Rate, (ii) the Federal Funds Rate plus 0.50% or (iii) the one-month Adjusted LIBOR plus 1.00%, plus, in each case, an interest rate margin. There were $230.5 million in borrowings outstanding on the term loan facility as of September 30, 2021. There were $171.0 million in borrowings outstanding under the revolving credit facility as of September 30, 2021. Our available borrowings on the revolving credit facility at September 30, 2021 were $411.5 million with approximately $2.5 million of the facility set aside for outstanding letters of credit. The seventh amended and restated senior credit agreement is collateralized by substantially all of our personal property and assets. The seventh amended and restated senior credit agreement contains covenants and restrictions which, among other things, require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of September 30, 2021. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds from any issuance of equity and asset sales. On January 29, 2019, we issued $345.0 million in 2.625% convertible notes due in 2024 (the "Notes"). Interest is payable semi-annually in arrears on February 1 and August 1 of each year, commencing August 1, 2019. The Notes will mature on February 1, 2024, unless earlier repurchased or converted. The Notes represent subordinated unsecured obligations and are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The Notes may be converted at an initial conversion rate of 11.2608 shares of our common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $88.80 per share of common stock). Holders of the Notes may convert the Notes at their option at any time on or after November 1, 2023 through the second scheduled trading day preceding the maturity date. Holders of the Notes will also have the right to convert the Notes prior to November 1, 2023, but only upon the occurrence of specified events. The conversion rate is subject to anti-dilution adjustments if certain events occur. A portion of the net proceeds from the offering of the Notes were used as part of the financing for the Buffalo Filter acquisition and $21.0 million were used to pay the cost of certain convertible notes hedge transactions as further described below. Our effective borrowing rate for nonconvertible debt at the time of issuance of the Notes was estimated to be 6.14%, which resulted in $51.6 million of the $345.0 million aggregate principal amount of Notes issued, or $39.1 million after taxes, being attributable to equity. For the three months ended September 30, 2021 and 2020, we have recorded interest expense related to the amortization of debt discount on the Notes of $2.6 million and $2.4 million, respectively, and for the nine months ended September 30, 2021 and 2020, we have recorded interest expense related to the amortization of debt discount on the Notes of $7.6 million and $7.2 million, respectively, at the effective interest rate of 6.14%. The debt discount on the Notes is being amortized through February 2024. For both the three months ended September 30, 2021 and 2020, we have recorded interest expense on the Notes of $2.3 million and for both the nine months ended September 30, 2021 and 2020, we have recorded interest expense on the Notes of $6.8 million at the contractual coupon rate of 2.625%. In connection with the offering of the Notes, we entered into convertible note hedge transactions with a number of financial institutions (each, an “option counterparty”). The convertible note hedge transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Notes, the number of shares of our common stock underlying the Notes. Concurrently with entering into the convertible note hedge transactions, we also entered into separate warrant transactions with each option counterparty whereby we sold to such option counterparty warrants to purchase, subject to customary anti-dilution adjustments, the same number of shares of our common stock. The convertible note hedge transactions are expected generally to reduce the potential dilution upon conversion of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, in the event that the market price per share of our common stock, as measured under the terms of the convertible note hedge transactions, is greater than the strike price of the convertible note hedge transactions, which initially corresponds to the conversion price of the Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the Notes. If, however, the market price per share of our common stock, as measured under the terms of the warrant transactions, exceeds the strike price ($114.92) of the warrants, there would nevertheless be dilution to the extent that such market price exceeds the strike price of the warrants as noted in Note 7, unless we elect to settle the warrants in cash. The scheduled maturities of long-term debt outstanding at September 30, 2021 are as follows: Remaining 2021 $ 2,981 2022 11,925 2023 14,906 2024 365,869 2025 23,850 2026 327,018 The above amounts exclude debt discount, deferred debt issuance costs and financing leases. |
Guarantees
Guarantees | 9 Months Ended |
Sep. 30, 2021 | |
Guarantees [Abstract] | |
Guarantees | GuaranteesWe provide warranties on certain of our products at the time of sale and sell extended warranties. The standard warranty period for our capital equipment is generally one year and our extended warranties typically vary from one to three years. Liability under warranty policies is based upon a review of historical claim experience. Adjustments are made to accruals as claim data and historical experience warrant. Changes in the liability for standard warranties for the nine months ended September 30, are as follows: 2021 2020 Balance as of January 1, $ 1,826 $ 2,186 Provision for warranties 1,235 616 Claims made (683) (932) Balance as of September 30, $ 2,378 $ 1,870 Costs associated with extended warranty repairs are recorded as incurred and amounted to $5.2 million and $4.4 million for the nine months ended September 30, 2021 and 2020, respectively. |
Pension Plan
Pension Plan | 9 Months Ended |
Sep. 30, 2021 | |
Retirement Benefits [Abstract] | |
Pension Plan | Pension Plan Net periodic pension cost consists of the following: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Service cost $ 248 $ 179 $ 744 $ 537 Interest cost on projected benefit obligation 451 639 1,353 1,917 Expected return on plan assets (1,289) (1,255) (3,867) (3,765) Net amortization and deferral 832 705 2,496 2,115 Net periodic pension cost $ 242 $ 268 $ 726 $ 804 |
Acquisition and Other Expense
Acquisition and Other Expense | 9 Months Ended |
Sep. 30, 2021 | |
Acquisition and Other Expense [Abstract] | |
Acquisition and Other Expense | Acquisition and Other Expense Acquisition and other expense consist of the following, which are included in cost of sales, selling and administrative expense or other expense depending on the nature of the charge: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Plant underutilization costs $ — $ — $ — $ 6,586 Product rationalization costs - inventory — — — 2,169 Restructuring costs — — — 1,087 Manufacturing consolidation costs — 606 — 3,993 Acquisition and integration costs — 796 — 2,253 Acquisition and other expense included in cost of sales $ — $ 1,402 $ — $ 16,088 Restructuring and related costs $ — $ 1,009 $ 414 $ 3,133 Product rationalization costs - field inventory — — — 2,095 Acquisition and integration costs — — — 1,192 Acquisition and other expense included in selling and administrative expense $ — $ 1,009 $ 414 $ 6,420 Debt refinancing costs included in other expense $ 1,127 $ — $ 1,127 $ — During the nine months ended September 30, 2020, we recorded a $6.6 million charge to cost of sales related to plant underutilization due to abnormally low production as a result of decreased sales caused by the COVID-19 pandemic. During the nine months ended September 30, 2020, we performed an analysis of our product lines and determined certain catalog numbers, principally related to capital equipment, would be discontinued and consolidated into existing product offerings. We consequently recorded a $2.2 million charge to cost of sales to write-off inventory of the discontinued products. In addition, we incurred $2.1 million in costs related to the write-off of field inventory used for customer demonstration and evaluation of the discontinued products which we charged to selling and administrative expense. During the nine months ended September 30, 2020, we incurred $1.1 million in restructuring costs related to a voluntary separation arrangement with employees as a result of the COVID-19 pandemic that were charged to cost of sales based on the job function of the affected employees. During the three and nine months ended September 30, 2020, we incurred $0.6 million and $4.0 million, respectively, in costs related to the consolidation of certain manufacturing operations which were charged to cost of sales. These costs related to winding down operations at certain locations and moving production lines to other facilities. During the three and nine months ended September 30, 2020, we incurred costs for inventory step-up adjustments and other costs of $0.8 million and $2.3 million, respectively, related to a previous acquisition, which were charged to cost of sales. During the three and nine months ended September 30, 2020 we recorded charges of $1.0 million and $2.3 million, respectively, primarily related to the restructuring of our Orthopedic sales force that was charged to selling and administrative expenses based on the nature of the costs and function of the affected employees. During the nine months ended September 30, 2021, we recorded a charge of $0.4 million related to the restructuring of our sales force which consisted primarily of termination payments to Orthopedic distributors made in exchange for ongoing assistance to transition to employee-based sales representatives and severance that was charged to selling and administrative expenses. During the nine months ended September 30, 2020, we incurred $0.8 million in restructuring charges principally related to a voluntary separation arrangement with employees as a result of the COVID-19 pandemic which were charged to selling and administrative expense based on the nature of the costs and function of the affected employees. During the nine months ended September 30, 2020, we incurred $1.2 million in severance and integration costs mainly related to the Buffalo Filter acquisition which were included in selling and administrative expense. During the three and nine months ended September 30, 2021, we recorded $1.1 million related to a loss on early extinguishment and third party fees associated with the seventh amended and restated senior credit agreement as further described in Note 9. These costs were included in other expense. |
Business Segment
Business Segment | 9 Months Ended |
Sep. 30, 2021 | |
Segment Reporting [Abstract] | |
Business Segment | Business Segment We are accounting and reporting for our business as a single operating segment entity engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Our chief operating decision maker (the CEO) evaluates the various global product portfolios on a net sales basis and evaluates profitability, investment, cash flow metrics and allocates resources on a consolidated worldwide basis due to shared infrastructure and resources. Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures and fees related to the sales representation, promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. These product lines' net sales are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Orthopedic surgery $ 105,751 $ 102,187 $ 320,809 $ 261,954 General surgery 143,076 135,648 415,856 347,677 Consolidated net sales $ 248,827 $ 237,835 $ 736,665 $ 609,631 |
Legal Proceedings
Legal Proceedings | 9 Months Ended |
Sep. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Legal Proceedings | Legal Proceedings From time to time, the Company may receive an information request, subpoena or warrant from a government agency such as the Securities and Exchange Commission, Department of Justice, Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, the United States Food and Drug Administration, the Department of Labor, the Treasury Department or other federal and state agencies or foreign governments or government agencies. These information requests, subpoenas or warrants may or may not be routine inquiries, or may begin as routine inquiries and over time develop into enforcement actions of various types. Likewise, if we receive reports of alleged misconduct from employees and third parties, we investigate as appropriate. Manufacturers of medical devices have been the subject of various enforcement actions relating to interactions with health care providers domestically or internationally whereby companies are claimed to have provided health care providers with inappropriate incentives to purchase their products. Similarly, the Foreign Corrupt Practices Act ("FCPA") imposes obligations on manufacturers with respect to interactions with health care providers who may be considered government officials based on their affiliation with public hospitals. The FCPA also requires publicly listed manufacturers to maintain accurate books and records, and maintain internal accounting controls sufficient to provide assurance that transactions are accurately recorded, lawful and in accordance with management's authorization. The FCPA poses unique challenges both because manufacturers operate in foreign cultures in which conduct illegal under the FCPA may not be illegal in local jurisdictions, and because, in some cases, a United States manufacturer may face risks under the FCPA based on the conduct of third parties over whom the manufacturer may not have complete control. While CONMED has not experienced any material enforcement action to date, there can be no assurance that the Company will not be subject to a material enforcement action in the future, or that the Company will not incur costs including, in the form of fees for lawyers and other consultants, that are material to the Company’s results of operations in the course of responding to a future inquiry or investigation. Manufacturers of medical products may face exposure to significant product liability claims, as well as patent infringement and other claims incurred in the ordinary course of business. To date, we have not experienced any claims that have been material to our financial statements or financial condition, but any such claims arising in the future could have a material adverse effect on our business, results of operations or cash flows. We currently maintain commercial product liability insurance of $35 million per incident and $35 million in the aggregate annually, which we believe is adequate. This coverage is on a claims-made basis. There can be no assurance that claims will not exceed insurance coverage, that the carriers will be solvent or that such insurance will be available to us in the future at a reasonable cost. Our operations are subject, and in the past have been subject, to a number of environmental laws and regulations governing, among other things, air emissions; wastewater discharges; the use, handling and disposal of hazardous substances and wastes; soil and groundwater remediation and employee health and safety. Likewise, the operations of our suppliers and sterilizers are subject to similar environmental laws and regulations. In some jurisdictions, environmental requirements may be expected to become more stringent in the future. In the United States, certain environmental laws can impose liability for the entire cost of site restoration upon each of the parties that may have contributed to conditions at the site regardless of fault or the lawfulness of the party’s activities. While we do not believe that the present costs of environmental compliance and remediation are material, there can be no assurance that future compliance or remedial obligations would not have a material adverse effect on our financial condition, results of operations or cash flows. In 2014, the Company acquired EndoDynamix, Inc. The agreement governing the terms of the acquisition provides that, if various conditions are met, certain contingent payments relating to the first commercial sale of the products (the milestone payment), as well as royalties based on sales (the revenue based payments), are due to the seller. In 2016, we notified the seller that there was a need to redesign the product, and that, as a consequence, the first commercial sale had been delayed. Consequently, the payment of contingent milestone and revenue-based payments were delayed. On January 18, 2017, the seller provided notice (the "Notice") seeking $12.7 million under a liquidated damages clause, which essentially represents the seller's view as to the sum of the projected contingent milestone and revenue-based payments on an accelerated basis. CONMED responded to the Notice denying that there was any basis for acceleration of the payments due under the acquisition agreement. On February 22, 2017, the representative of the former shareholders of EndoDynamix filed a complaint in Delaware Chancery Court claiming breach of contract with respect to the duty to commercialize the product and seeking the contingent payments on an accelerated basis. We believe that there was a substantive contractual basis to support the Company's decision to redesign the product, such that there was no legitimate basis for seeking the liquidated damages. In the third quarter of 2018, the Company decided to halt the development of the EndoDynamix clip applier and recorded a charge to write off assets and released a previously accrued contingent consideration liability. In court filings the Plaintiffs claim to seek liquidated damages, as well as additional damages up to $24.8 million. A non-jury trial in the Delaware Chancery Court commenced on March 18, 2021, and testimony concluded on April 7, 2021. The parties have submitted post-trial briefs, and the Court heard oral arguments at a hearing on September 16, 2021. The Court has not yet issued a ruling. The Company has not recorded any expense related to potential damages in connection with this matter because the Company does not believe any potential loss is probable. We expect to defend the claims asserted by the sellers of EndoDynamix, although there can be no assurance that we will prevail in the trial and/or any resulting appeals. CONMED is defending two Georgia State Court actions. The first was filed by various employees, former employees, contract workers and others against CONMED, and against a contract sterilizer. The second action is against CONMED’s landlord and other allegedly related entities. Plaintiffs in the lawsuits allege personal injury and related claims purportedly arising from or relating to exposure to Ethylene Oxide, a chemical used to sterilize certain products. CONMED is defending the claims asserted directly against it and is providing indemnification for certain other defendants based on contractual provisions. CONMED has submitted all of the claims for insurance coverage. One insurer is providing coverage for certain of the claims asserted directly against the Company. CONMED is currently in litigation with one of the other insurers regarding coverage for certain of the indemnification claims. The Company is unable to estimate any range of possible loss at this time, and has not recorded any expense related to potential damages in connection with this matter because the Company does not believe any potential loss is probable. Both actions are in their early stages and discovery has not yet started. CONMED believes it has strong defenses to the claims and will vigorously defend itself and all parties it is indemnifying. As with any litigation, there are risks, including the risk that CONMED may not prevail with respect to the defense of the underlying claims, or with respect to securing adequate insurance coverage for the indemnification claims. We record reserves sufficient to cover probable and estimable losses associated with any such pending claims. We do not expect that the resolution of any pending claims, investigations or reports of alleged misconduct will have a material adverse effect on our financial condition, results of operations or cash flows. There can be no assurance, however, that future claims or investigations, or the costs associated with responding to such claims, investigations or reports of misconduct, especially claims and investigations not covered by insurance, will not have a material adverse effect on our financial condition, results of operations or cash flows. |
New Accounting Pronouncements
New Accounting Pronouncements | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Standards Update and Change in Accounting Principle [Abstract] | |
New Accounting Pronouncements | New Accounting Pronouncements Recently Issued Accounting Standards, Not Yet Adopted In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional guidance if certain criteria are met for entities that have contracts, hedging relationships, and other transactions that reference LIBOR or other reference rates expected to be discontinued as a result of reference rate reform. This ASU is effective as of March 12, 2020 through December 31, 2022. The Company has not adopted this ASU as of September 30, 2021, however will continue to monitor the impact of reference rates and will elect to apply this guidance in our consolidated financial statements in the event that we are impacted by reference rate reform. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing certain separation models requiring separate accounting for embedded conversion features which will result in more convertible debt instruments accounted for as a single liability. The ASU eliminates certain settlement conditions that are required for equity classification to qualify for the derivative scope exception. The ASU addresses how convertible instruments are accounted for in the calculation of diluted earnings per share by using the if-converted method. The ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company will adopt this standard on January 1, 2022 using the modified retrospective method. The estimated impacts include the convertible debt instrument being accounted for as a single liability measured at its amortized cost and elimination of the non-cash interest expense as the Company will not separately present the equity embedded conversion feature in such debt. The Company also expects to adopt the if-converted method for earnings per share. |
Interim Reporting (Policies)
Interim Reporting (Policies) | 9 Months Ended |
Sep. 30, 2021 | |
Quarterly Financial Information Disclosure [Abstract] | |
Use of Estimates | Use of Estimates Preparation of the consolidated condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the reported amounts of revenue and expenses during the reporting period. |
New Accounting Pronouncements (
New Accounting Pronouncements (Policies) | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Standards Update and Change in Accounting Principle [Abstract] | |
New Accounting Pronouncements | New Accounting Pronouncements Recently Issued Accounting Standards, Not Yet Adopted In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional guidance if certain criteria are met for entities that have contracts, hedging relationships, and other transactions that reference LIBOR or other reference rates expected to be discontinued as a result of reference rate reform. This ASU is effective as of March 12, 2020 through December 31, 2022. The Company has not adopted this ASU as of September 30, 2021, however will continue to monitor the impact of reference rates and will elect to apply this guidance in our consolidated financial statements in the event that we are impacted by reference rate reform. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing certain separation models requiring separate accounting for embedded conversion features which will result in more convertible debt instruments accounted for as a single liability. The ASU eliminates certain settlement conditions that are required for equity classification to qualify for the derivative scope exception. The ASU addresses how convertible instruments are accounted for in the calculation of diluted earnings per share by using the if-converted method. The ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company will adopt this standard on January 1, 2022 using the modified retrospective method. The estimated impacts include the convertible debt instrument being accounted for as a single liability measured at its amortized cost and elimination of the non-cash interest expense as the Company will not separately present the equity embedded conversion feature in such debt. The Company also expects to adopt the if-converted method for earnings per share. |
Revenues (Tables)
Revenues (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue | The following tables present revenue disaggregated by primary geographic market where the products are sold, by product line and timing of revenue recognition: Three Months Ended Three Months Ended September 30, 2021 September 30, 2020 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 37,957 $ 98,444 $ 136,401 $ 38,913 $ 95,292 $ 134,205 Europe, Middle East & Africa 24,155 19,905 44,060 23,104 17,584 40,688 Asia Pacific 27,517 16,113 43,630 26,403 15,405 41,808 Americas (excluding the United States) 16,122 8,614 24,736 13,767 7,367 21,134 Total sales from contracts with customers $ 105,751 $ 143,076 $ 248,827 $ 102,187 $ 135,648 $ 237,835 Timing of Revenue Recognition Goods transferred at a point in time $ 96,389 $ 141,798 $ 238,187 $ 93,000 $ 134,745 $ 227,745 Services transferred over time 9,362 1,278 10,640 9,187 903 10,090 Total sales from contracts with customers $ 105,751 $ 143,076 $ 248,827 $ 102,187 $ 135,648 $ 237,835 Nine Months Ended Nine Months Ended September 30, 2021 September 30, 2020 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 115,864 $ 288,069 $ 403,933 $ 97,339 $ 243,137 $ 340,476 Europe, Middle East & Africa 77,327 58,594 135,921 62,726 50,345 113,071 Asia Pacific 80,403 44,911 125,314 66,737 34,211 100,948 Americas (excluding the United States) 47,215 24,282 71,497 35,152 19,984 55,136 Total sales from contracts with customers $ 320,809 $ 415,856 $ 736,665 $ 261,954 $ 347,677 $ 609,631 Timing of Revenue Recognition Goods transferred at a point in time $ 291,728 $ 412,298 $ 704,026 $ 237,224 $ 345,068 $ 582,292 Services transferred over time 29,081 3,558 32,639 24,730 2,609 27,339 Total sales from contracts with customers $ 320,809 $ 415,856 $ 736,665 $ 261,954 $ 347,677 $ 609,631 |
Contract with Customer, Asset and Liability | Contract liability balances related to the sale of extended warranties to customers are as follows: September 30, 2021 December 31, 2020 Contract liability $ 15,833 $ 13,666 |
Comprehensive Income (Loss) (Ta
Comprehensive Income (Loss) (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Equity [Abstract] | |
Schedule of Comprehensive Income (Loss) | Comprehensive income (loss) consists of the following: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net income (loss) $ 14,948 $ 6,850 $ 38,098 $ (14,623) Other comprehensive income (loss): Cash flow hedging gain (loss), net of income tax (income tax expense (benefit) of $929 and $(964) for the three months ended September 30, 2021 and 2020, respectively, and $2,568 and $(972) for the nine months ended September 30, 2021 and 2020, respectively) 2,917 (3,026) 8,064 (3,050) Pension liability, net of income tax (income tax expense of $201 and $170 for the three months ended September 30, 2021 and 2020, respectively, and $603 and $510 for the nine months ended September 30, 2021 and 2020, respectively) 631 535 1,893 1,605 Foreign currency translation adjustment (4,740) 4,617 (5,813) (790) Comprehensive income (loss) $ 13,756 $ 8,976 $ 42,242 $ (16,858) |
Schedule of Accumulated Other Comprehensive Loss | Accumulated other comprehensive loss consists of the following: Cash Flow Pension Cumulative Accumulated Balance, December 31, 2020 $ (5,945) $ (36,620) $ (21,116) $ (63,681) Other comprehensive income (loss) before reclassifications, net of tax 5,141 — (5,813) (672) Amounts reclassified from accumulated other comprehensive income (loss) before tax a 3,854 2,496 — 6,350 Income tax (931) (603) — (1,534) Net current-period other comprehensive income (loss) 8,064 1,893 (5,813) 4,144 Balance, September 30, 2021 $ 2,119 $ (34,727) $ (26,929) $ (59,537) Cash Flow Pension Cumulative Accumulated Balance, December 31, 2019 $ 493 $ (31,691) $ (28,079) $ (59,277) Other comprehensive income (loss) before reclassifications, net of tax (1,916) — (790) (2,706) Amounts reclassified from accumulated other comprehensive income (loss) before tax a (1,496) 2,115 — 619 Income tax 362 (510) — (148) Net current-period other comprehensive income (loss) (3,050) 1,605 (790) (2,235) Balance, September 30, 2020 $ (2,557) $ (30,086) $ (28,869) $ (61,512) (a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 5 and Note 11, respectively, for further details. |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of Notional Amounts of Outstanding Derivative Positions | The following table presents the notional contract amounts for forward contracts outstanding: As of FASB ASC Topic 815 Designation September 30, 2021 December 31, 2020 Forward exchange contracts Cash flow hedge $ 178,908 $ 154,504 Forward exchange contracts Non-designated 37,254 42,380 |
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) | Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) ("AOCI") and net earnings on our consolidated condensed statements of comprehensive income (loss) and our consolidated condensed balance sheets: Amount of Gain (Loss) Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Three Months Ended September 30, Total Amount of Line Item Presented Derivative Instrument 2021 2020 Location of amount reclassified 2021 2020 2021 2020 Foreign exchange contracts $ 3,188 $ (3,542) Net Sales $ 248,827 $ 237,835 $ (1,077) $ 663 Cost of Sales 106,521 104,137 419 (215) Pre-tax gain (loss) $ 3,188 $ (3,542) $ (658) $ 448 Tax expense (benefit) 770 (856) (159) 108 Net gain (loss) $ 2,418 $ (2,686) $ (499) $ 340 Amount of Gain (Loss) Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Nine Months Ended September 30, Total Amount of Line Item Presented Derivative Instrument 2021 2020 Location of amount reclassified 2021 2020 2021 2020 Foreign exchange contracts $ 6,778 $ (2,526) Net Sales $ 736,665 $ 609,631 $ (4,948) $ 2,206 Cost of Sales 324,485 284,845 1,094 (710) Pre-tax gain (loss) $ 6,778 $ (2,526) $ (3,854) $ 1,496 Tax expense (benefit) 1,637 (610) (931) 362 Net gain (loss) $ 5,141 $ (1,916) $ (2,923) $ 1,134 |
Derivatives Not Designated as Hedging Instruments | Net losses from derivative instruments not accounted for as hedges and gains and losses on our intercompany receivables on our consolidated condensed statements of comprehensive income (loss) were: Three Months Ended September 30, Nine Months Ended September 30, Derivative Instrument Location on Consolidated Condensed Statements of Comprehensive Income (Loss) 2021 2020 2021 2020 Net loss on currency forward contracts Selling and administrative expense $ (48) $ (682) $ (398) $ (1,224) Net gain (loss) on currency transaction exposures Selling and administrative expense $ (441) $ 312 $ (1,320) $ 143 |
Schedule of Fair Value for Forward Foreign Exchange Contracts | The following tables summarize the fair value for forward foreign exchange contracts outstanding at September 30, 2021 and December 31, 2020: September 30, 2021 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Prepaid expenses and other current assets $ 3,319 $ (1,311) $ 2,008 Foreign exchange contracts Other long-term assets 932 (145) 787 $ 4,251 $ (1,456) $ 2,795 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 21 (160) (139) Total derivatives $ 4,272 $ (1,616) $ 2,656 December 31, 2020 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Other current liabilities $ 1,500 $ (8,826) $ (7,326) Foreign exchange contracts Other long-term liabilities 23 (535) (512) $ 1,523 $ (9,361) $ (7,838) Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 25 (150) (125) Total derivatives $ 1,548 $ (9,511) $ (7,963) |
Inventories (Tables)
Inventories (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Inventory Disclosure [Abstract] | |
Schedule of inventory | Inventories consist of the following: September 30, December 31, Raw materials $ 76,637 $ 71,807 Work-in-process 17,658 15,864 Finished goods 134,277 107,197 Total $ 228,572 $ 194,868 |
Earnings (Loss) Per Share (Tabl
Earnings (Loss) Per Share (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of calculation of basic and diluted earnings (loss) per share | The following table sets forth the computation of basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net income (loss) $ 14,948 $ 6,850 $ 38,098 $ (14,623) Basic – weighted average shares outstanding 29,179 28,583 29,097 28,529 Effect of dilutive potential securities 2,964 843 2,923 — Diluted – weighted average shares outstanding 32,143 29,426 32,020 28,529 Net income (loss) (per share) Basic $ 0.51 $ 0.24 $ 1.31 $ (0.51) Diluted 0.47 0.23 1.19 (0.51) |
Goodwill and Other Intangible_2
Goodwill and Other Intangible Assets (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | The changes in the net carrying amount of goodwill for the nine months ended September 30, 2021 are as follows: Balance as of December 31, 2020 $ 618,440 Foreign currency translation (789) Balance as of September 30, 2021 $ 617,651 |
Schedule of Finite-Lived Intangible Assets | Other intangible assets consist of the following: September 30, 2021 December 31, 2020 Weighted Average Amortization Period (Years) Gross Accumulated Gross Accumulated Intangible assets with definite lives: 22 Customer and distributor relationships 24 $ 342,501 $ (148,330) $ 342,639 $ (134,555) Sales representation, marketing and promotional rights 25 149,376 (58,500) 149,376 (54,000) Developed technology 16 106,604 (24,801) 106,604 (19,705) Patents and other intangible assets 16 75,836 (50,369) 73,516 (48,882) Intangible assets with indefinite lives: Trademarks and tradenames 86,544 — 86,544 — $ 760,861 $ (282,000) $ 758,679 $ (257,142) |
Schedule of Indefinite-Lived Intangible Assets | Other intangible assets consist of the following: September 30, 2021 December 31, 2020 Weighted Average Amortization Period (Years) Gross Accumulated Gross Accumulated Intangible assets with definite lives: 22 Customer and distributor relationships 24 $ 342,501 $ (148,330) $ 342,639 $ (134,555) Sales representation, marketing and promotional rights 25 149,376 (58,500) 149,376 (54,000) Developed technology 16 106,604 (24,801) 106,604 (19,705) Patents and other intangible assets 16 75,836 (50,369) 73,516 (48,882) Intangible assets with indefinite lives: Trademarks and tradenames 86,544 — 86,544 — $ 760,861 $ (282,000) $ 758,679 $ (257,142) |
Schedule of Estimated Amortization Expense | The estimated intangible asset amortization expense remaining for the year ending December 31, 2021 and for each of the five succeeding years is as follows: Amortization included in expense Amortization recorded as a reduction of revenue Total Remaining, 2021 $ 7,187 $ 1,500 $ 8,687 2022 26,554 6,000 32,554 2023 25,679 6,000 31,679 2024 24,929 6,000 30,929 2025 25,145 6,000 31,145 2026 24,652 6,000 30,652 |
Long Term Debt (Tables)
Long Term Debt (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of Long-term Debt | Long-term debt consists of the following: September 30, 2021 December 31, 2020 Revolving line of credit $ 171,000 $ 207,000 Term loan, net of deferred debt issuance costs of $1,448 and $1,668 in 2021 and 2020, respectively 229,102 240,145 2.625% convertible notes, net of deferred debt issuance costs of $4,144 and $5,475 in 2021 and 2020, respectively, and unamortized discount of $26,009 and $33,620 in 2021 and 2020, respectively 314,846 305,904 Financing leases 638 587 Total debt 715,586 753,636 Less: Current portion 12,251 18,415 Total long-term debt $ 703,335 $ 735,221 |
Schedule of Maturities of Long-term Debt | The scheduled maturities of long-term debt outstanding at September 30, 2021 are as follows: Remaining 2021 $ 2,981 2022 11,925 2023 14,906 2024 365,869 2025 23,850 2026 327,018 The above amounts exclude debt discount, deferred debt issuance costs and financing leases. |
Guarantees (Tables)
Guarantees (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Guarantees [Abstract] | |
Changes in the carrying amount of service and product warranties | Changes in the liability for standard warranties for the nine months ended September 30, are as follows: 2021 2020 Balance as of January 1, $ 1,826 $ 2,186 Provision for warranties 1,235 616 Claims made (683) (932) Balance as of September 30, $ 2,378 $ 1,870 |
Pension Plan (Tables)
Pension Plan (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Retirement Benefits [Abstract] | |
Schedule of net benefit cost | Net periodic pension cost consists of the following: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Service cost $ 248 $ 179 $ 744 $ 537 Interest cost on projected benefit obligation 451 639 1,353 1,917 Expected return on plan assets (1,289) (1,255) (3,867) (3,765) Net amortization and deferral 832 705 2,496 2,115 Net periodic pension cost $ 242 $ 268 $ 726 $ 804 |
Acquisition and Other Expense (
Acquisition and Other Expense (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Acquisition and Other Expense [Abstract] | |
Schedule of Acquisition and Other Operating Expense | Acquisition and other expense consist of the following, which are included in cost of sales, selling and administrative expense or other expense depending on the nature of the charge: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Plant underutilization costs $ — $ — $ — $ 6,586 Product rationalization costs - inventory — — — 2,169 Restructuring costs — — — 1,087 Manufacturing consolidation costs — 606 — 3,993 Acquisition and integration costs — 796 — 2,253 Acquisition and other expense included in cost of sales $ — $ 1,402 $ — $ 16,088 Restructuring and related costs $ — $ 1,009 $ 414 $ 3,133 Product rationalization costs - field inventory — — — 2,095 Acquisition and integration costs — — — 1,192 Acquisition and other expense included in selling and administrative expense $ — $ 1,009 $ 414 $ 6,420 Debt refinancing costs included in other expense $ 1,127 $ — $ 1,127 $ — |
Business Segment (Tables)
Business Segment (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Segment Reporting [Abstract] | |
Schedule of net sales information by product line | These product lines' net sales are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Orthopedic surgery $ 105,751 $ 102,187 $ 320,809 $ 261,954 General surgery 143,076 135,648 415,856 347,677 Consolidated net sales $ 248,827 $ 237,835 $ 736,665 $ 609,631 |
Revenues (Disaggregated Revenue
Revenues (Disaggregated Revenues) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Disaggregation of Revenue [Line Items] | ||||
Net Sales | $ 248,827 | $ 237,835 | $ 736,665 | $ 609,631 |
Goods transferred at a point in time | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 238,187 | 227,745 | 704,026 | 582,292 |
Services transferred over time | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 10,640 | 10,090 | 32,639 | 27,339 |
Orthopedic Surgery | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 105,751 | 102,187 | 320,809 | 261,954 |
Orthopedic Surgery | Goods transferred at a point in time | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 96,389 | 93,000 | 291,728 | 237,224 |
Orthopedic Surgery | Services transferred over time | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 9,362 | 9,187 | 29,081 | 24,730 |
General Surgery | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 143,076 | 135,648 | 415,856 | 347,677 |
General Surgery | Goods transferred at a point in time | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 141,798 | 134,745 | 412,298 | 345,068 |
General Surgery | Services transferred over time | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 1,278 | 903 | 3,558 | 2,609 |
United States | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 136,401 | 134,205 | 403,933 | 340,476 |
United States | Orthopedic Surgery | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 37,957 | 38,913 | 115,864 | 97,339 |
United States | General Surgery | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 98,444 | 95,292 | 288,069 | 243,137 |
Americas (excluding the United States) | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 24,736 | 21,134 | 71,497 | 55,136 |
Americas (excluding the United States) | Orthopedic Surgery | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 16,122 | 13,767 | 47,215 | 35,152 |
Americas (excluding the United States) | General Surgery | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 8,614 | 7,367 | 24,282 | 19,984 |
Europe, Middle East & Africa | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 44,060 | 40,688 | 135,921 | 113,071 |
Europe, Middle East & Africa | Orthopedic Surgery | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 24,155 | 23,104 | 77,327 | 62,726 |
Europe, Middle East & Africa | General Surgery | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 19,905 | 17,584 | 58,594 | 50,345 |
Asia Pacific | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 43,630 | 41,808 | 125,314 | 100,948 |
Asia Pacific | Orthopedic Surgery | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | 27,517 | 26,403 | 80,403 | 66,737 |
Asia Pacific | General Surgery | ||||
Disaggregation of Revenue [Line Items] | ||||
Net Sales | $ 16,113 | $ 15,405 | $ 44,911 | $ 34,211 |
Revenues (Customer Liability) (
Revenues (Customer Liability) (Details) - USD ($) $ in Thousands | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | |
Revenue from Contract with Customer [Abstract] | |||
Contract liability | $ 15,833 | $ 13,666 | |
Revenue recognized | $ 8,400 | $ 7,600 |
Comprehensive Income (Loss) (De
Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Equity [Abstract] | ||||||||
Net income (loss) | $ 14,948 | $ 6,850 | $ 38,098 | $ (14,623) | ||||
Cash flow hedging gain (loss), net | 2,917 | (3,026) | 8,064 | (3,050) | ||||
Pension liability, net of income tax | 631 | 535 | 1,893 | 1,605 | ||||
Foreign currency translation adjustments | (4,740) | 4,617 | (5,813) | (790) | ||||
Comprehensive income (loss) | 13,756 | $ 17,743 | $ 10,743 | 8,976 | $ (24,713) | $ (1,121) | 42,242 | (16,858) |
Pension liability, tax | 201 | 170 | 603 | 510 | ||||
Cash flow hedging gain (loss), tax | $ 929 | $ (964) | $ 2,568 | $ (972) |
Comprehensive Income (Loss) (Ac
Comprehensive Income (Loss) (Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | ||
Accumulated other comprehensive income (loss) [Roll Forward] | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | $ (63,681) | ||
Accumulated Other Comprehensive Income (Loss), Net of Tax | (59,537) | ||
Accumulated Other Comprehensive Loss | |||
Accumulated other comprehensive income (loss) [Roll Forward] | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | (63,681) | $ (59,277) | |
Other comprehensive income (loss) before reclassifications, net of tax | (672) | (2,706) | |
Amounts reclassified from other accumulated comprehensive income (loss) before tax | [1] | 6,350 | 619 |
Reclassification from AOCI, Current Period, Tax | (1,534) | (148) | |
Net current-period other comprehensive income (loss) | 4,144 | (2,235) | |
Accumulated Other Comprehensive Income (Loss), Net of Tax | (59,537) | (61,512) | |
Cash Flow Hedging Gain (Loss) | |||
Accumulated other comprehensive income (loss) [Roll Forward] | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | (5,945) | 493 | |
Other comprehensive income (loss) before reclassifications, net of tax | 5,141 | (1,916) | |
Amounts reclassified from other accumulated comprehensive income (loss) before tax | [1] | 3,854 | (1,496) |
Reclassification from AOCI, Current Period, Tax | (931) | 362 | |
Net current-period other comprehensive income (loss) | 8,064 | (3,050) | |
Accumulated Other Comprehensive Income (Loss), Net of Tax | 2,119 | (2,557) | |
Pension Liability | |||
Accumulated other comprehensive income (loss) [Roll Forward] | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | (36,620) | (31,691) | |
Other comprehensive income (loss) before reclassifications, net of tax | 0 | 0 | |
Amounts reclassified from other accumulated comprehensive income (loss) before tax | [1] | 2,496 | 2,115 |
Reclassification from AOCI, Current Period, Tax | (603) | (510) | |
Net current-period other comprehensive income (loss) | 1,893 | 1,605 | |
Accumulated Other Comprehensive Income (Loss), Net of Tax | (34,727) | (30,086) | |
Cumulative Translation Adjustments | |||
Accumulated other comprehensive income (loss) [Roll Forward] | |||
Accumulated Other Comprehensive Income (Loss), Net of Tax | (21,116) | (28,079) | |
Other comprehensive income (loss) before reclassifications, net of tax | (5,813) | (790) | |
Amounts reclassified from other accumulated comprehensive income (loss) before tax | [1] | 0 | 0 |
Reclassification from AOCI, Current Period, Tax | 0 | 0 | |
Net current-period other comprehensive income (loss) | (5,813) | (790) | |
Accumulated Other Comprehensive Income (Loss), Net of Tax | $ (26,929) | $ (28,869) | |
[1] | The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 5 and Note 11, respectively, for further details. |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments (Amounts Recorded In and Reclassified From AOCI) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Net sales | $ 248,827 | $ 237,835 | $ 736,665 | $ 609,631 |
Cost of sales | 106,521 | 104,137 | 324,485 | 284,845 |
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax | 3,188 | (3,542) | 6,778 | (2,526) |
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax | 770 | (856) | 1,637 | (610) |
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax | 2,418 | (2,686) | 5,141 | (1,916) |
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax | (658) | 448 | (3,854) | 1,496 |
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax | (159) | 108 | (931) | 362 |
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax | (499) | 340 | (2,923) | 1,134 |
Revenues | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax | (1,077) | 663 | (4,948) | 2,206 |
Cost of Sales | ||||
Derivative Instruments, Gain (Loss) [Line Items] | ||||
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax | $ 419 | $ (215) | $ 1,094 | $ (710) |
Fair Value of Financial Instr_4
Fair Value of Financial Instruments (Foreign Currency Forward Contracts) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | |
Derivative [Line Items] | |||||
Foreign Currency Transaction Gain (Loss), before Tax | $ (441) | $ 312 | $ (1,320) | $ 143 | |
Derivative Assets and Liabilities at Fair Value [Abstract] | |||||
Asset Fair Value | 4,272 | 4,272 | $ 1,548 | ||
Liabilities Fair Value | (1,616) | (1,616) | (9,511) | ||
Net Fair Value | 2,656 | 2,656 | (7,963) | ||
Foreign Currency Forward Contracts | |||||
Derivative [Line Items] | |||||
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments | (48) | $ (682) | (398) | $ (1,224) | |
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | |||||
Derivative Assets and Liabilities at Fair Value [Abstract] | |||||
Asset Fair Value | 4,251 | 4,251 | 1,523 | ||
Liabilities Fair Value | (1,456) | (1,456) | (9,361) | ||
Net Fair Value | 2,795 | 2,795 | (7,838) | ||
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Prepaid Expenses and Other Current Assets [Member] | |||||
Derivative Assets and Liabilities at Fair Value [Abstract] | |||||
Asset Fair Value | 3,319 | 3,319 | |||
Liabilities Fair Value | (1,311) | (1,311) | |||
Net Fair Value | 2,008 | 2,008 | |||
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Other Noncurrent Liabilities [Member] | |||||
Derivative Assets and Liabilities at Fair Value [Abstract] | |||||
Asset Fair Value | 23 | ||||
Liabilities Fair Value | (535) | ||||
Net Fair Value | (512) | ||||
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Other Current Liabilities [Member] | |||||
Derivative Assets and Liabilities at Fair Value [Abstract] | |||||
Asset Fair Value | 1,500 | ||||
Liabilities Fair Value | (8,826) | ||||
Net Fair Value | (7,326) | ||||
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Other Noncurrent Assets [Member] | |||||
Derivative Assets and Liabilities at Fair Value [Abstract] | |||||
Asset Fair Value | 932 | 932 | |||
Liabilities Fair Value | (145) | (145) | |||
Net Fair Value | 787 | $ 787 | |||
Derivatives not designated as hedging instruments: | Foreign Currency Forward Contracts | |||||
Derivative [Line Items] | |||||
Maximum Length of Time Hedged in Cash Flow Hedge | 1 month | ||||
Notional amount of cash flow hedges | 37,254 | $ 37,254 | 42,380 | ||
Derivatives not designated as hedging instruments: | Foreign Currency Forward Contracts | Other Current Liabilities [Member] | |||||
Derivative Assets and Liabilities at Fair Value [Abstract] | |||||
Asset Fair Value | 21 | 21 | 25 | ||
Liabilities Fair Value | (160) | (160) | (150) | ||
Net Fair Value | (139) | $ (139) | (125) | ||
Cash flow hedge | Foreign Currency Forward Contracts | |||||
Derivative [Line Items] | |||||
Maximum Length of Time Hedged in Cash Flow Hedge | 2 years | ||||
Notional amount of cash flow hedges | 178,908 | $ 178,908 | $ 154,504 | ||
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months | $ 1,500 | $ 1,500 |
Inventories (Details)
Inventories (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 76,637 | $ 71,807 |
Work-in-process | 17,658 | 15,864 |
Finished goods | 134,277 | 107,197 |
Total inventory | $ 228,572 | $ 194,868 |
Earnings (Loss) Per Share (Deta
Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Earnings Per Share [Abstract] | ||||
Net income (loss) | $ 14,948 | $ 6,850 | $ 38,098 | $ (14,623) |
Basic-weighted average shares outstanding (in shares) | 29,179 | 28,583 | 29,097 | 28,529 |
Effect of dilutive potential securities (in shares) | 2,964 | 843 | 2,923 | 0 |
Diluted- weighted average shares outstanding (in shares) | 32,143 | 29,426 | 32,020 | 28,529 |
Basic (in dollars per share) | $ 0.51 | $ 0.24 | $ 1.31 | $ (0.51) |
Diluted (in dollars per share) | $ 0.47 | $ 0.23 | $ 1.19 | $ (0.51) |
Antidilutive securities excluded from computation of earnings per share (in shares) | 700 | 1,600 | 500 | |
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities | 1,200 | 1,200 | ||
Incremental Common Shares Attributable to Dilutive Effect of Warrants | 500 | 400 |
Earnings (Loss) Per Share - Con
Earnings (Loss) Per Share - Convertible Notes (Details) - Convertible Notes Payable - 2.625 Percent Convertible Notes Due 2024 [Member] | Jan. 29, 2019$ / shares |
Debt Instrument [Line Items] | |
Interest rate, stated percentage | 2.625% |
Conversion price (in dollars per share) | $ 88.80 |
Hedge transactions | |
Debt Instrument [Line Items] | |
Option indexed to issuer's equity, strike price (in dollars per share) | 114.92 |
Warrant | |
Debt Instrument [Line Items] | |
Option indexed to issuer's equity, strike price (in dollars per share) | $ 114.92 |
Goodwill and Other Intangible_3
Goodwill and Other Intangible Assets (Goodwill) (Details) $ in Thousands | 9 Months Ended |
Sep. 30, 2021USD ($) | |
Goodwill [Roll Forward] | |
Beginning balance | $ 618,440 |
Foreign currency translation | (789) |
Ending balance | $ 617,651 |
Goodwill and Other Intangible_4
Goodwill and Other Intangible Assets (Intangible Assets) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | |
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Intangible assets, Gross carrying amount | $ 760,861 | $ 760,861 | $ 758,679 | ||
Intangible assets, Accumulated amortization | (282,000) | (282,000) | (257,142) | ||
Amortization expense | 8,300 | $ 8,600 | 24,900 | $ 25,600 | |
Payments for Contingent Consideration | 3,536 | $ 2,071 | |||
Future amortization expense [Abstract] | |||||
Remaining, 2021 | 8,687 | 8,687 | |||
2022 | 32,554 | 32,554 | |||
2023 | 31,679 | 31,679 | |||
2024 | 30,929 | 30,929 | |||
2025 | 31,145 | 31,145 | |||
2026 | 30,652 | 30,652 | |||
Amortization included in expense | |||||
Future amortization expense [Abstract] | |||||
Remaining, 2021 | 7,187 | 7,187 | |||
2022 | 26,554 | 26,554 | |||
2023 | 25,679 | 25,679 | |||
2024 | 24,929 | 24,929 | |||
2025 | 25,145 | 25,145 | |||
2026 | 24,652 | 24,652 | |||
Amortization recorded as a reduction of revenue | |||||
Future amortization expense [Abstract] | |||||
Remaining, 2021 | 1,500 | 1,500 | |||
2022 | 6,000 | 6,000 | |||
2023 | 6,000 | 6,000 | |||
2024 | 6,000 | 6,000 | |||
2025 | 6,000 | 6,000 | |||
2026 | 6,000 | 6,000 | |||
Trademarks & tradenames | |||||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Unamortized intangible assets, Gross carrying amount | 86,544 | 86,544 | 86,544 | ||
Customer and distributor relationships | |||||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Amortized intangible assets, Gross carrying amount | 342,501 | 342,501 | 342,639 | ||
Intangible assets, Accumulated amortization | (148,330) | (148,330) | (134,555) | ||
Sales representation, marketing and promotional rights | |||||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Amortized intangible assets, Gross carrying amount | 149,376 | 149,376 | 149,376 | ||
Intangible assets, Accumulated amortization | (58,500) | (58,500) | (54,000) | ||
Patents and other intangible assets | |||||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Amortized intangible assets, Gross carrying amount | 75,836 | 75,836 | 73,516 | ||
Intangible assets, Accumulated amortization | (50,369) | (50,369) | (48,882) | ||
Developed technology | |||||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Amortized intangible assets, Gross carrying amount | 106,604 | 106,604 | 106,604 | ||
Intangible assets, Accumulated amortization | (24,801) | (24,801) | $ (19,705) | ||
Payments for Contingent Consideration | 3,500 | 3,500 | |||
Asset acquisition, contingent consideration liability | $ 2,400 | $ 2,400 | |||
Weighted Average | |||||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Finite-lived intangible asset useful life (in years) | 22 years | ||||
Weighted Average | Customer and distributor relationships | |||||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Finite-lived intangible asset useful life (in years) | 24 years | ||||
Weighted Average | Sales representation, marketing and promotional rights | |||||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Finite-lived intangible asset useful life (in years) | 25 years | ||||
Weighted Average | Patents and other intangible assets | |||||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Finite-lived intangible asset useful life (in years) | 16 years | ||||
Weighted Average | Developed technology | |||||
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items] | |||||
Finite-lived intangible asset useful life (in years) | 16 years |
Long Term Debt (Details)
Long Term Debt (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Debt Instrument [Line Items] | ||
Long-term Debt and Lease Obligation, Including Current Maturities | $ 715,586 | $ 753,636 |
Finance Lease, Liability | 638 | 587 |
Current portion of long-term debt | 12,251 | 18,415 |
Long-term debt | 703,335 | 735,221 |
Line of Credit [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt | 171,000 | 207,000 |
Term Loan Facility [Member] | ||
Debt Instrument [Line Items] | ||
Long-term Debt | 229,102 | 240,145 |
Unamortized Debt Issuance Expense | 1,448 | 1,668 |
Convertible Notes Payable [Member] | ||
Debt Instrument [Line Items] | ||
Convertible Debt | 314,846 | 305,904 |
Debt Instrument, Unamortized Discount | 26,009 | 33,620 |
Unamortized Debt Issuance Expense | $ 4,144 | $ 5,475 |
Long Term Debt Additional Infor
Long Term Debt Additional Information (Details) | Jan. 29, 2019USD ($)$ / shares | Sep. 30, 2021USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2021USD ($) | Sep. 30, 2020USD ($) | Jul. 16, 2021USD ($) | Dec. 31, 2020USD ($) |
Debt Instrument [Line Items] | |||||||
Amortization of debt discount | $ 7,611,000 | $ 7,239,000 | |||||
Term Loan Facility [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Long-term Debt, Gross | $ 230,500,000 | 230,500,000 | |||||
Long-term Debt | 229,102,000 | 229,102,000 | $ 240,145,000 | ||||
Term Loan Facility [Member] | Amended and Restated Senior Credit Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Face Amount | $ 233,500,000 | ||||||
Line of Credit [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Long-term Debt | 171,000,000 | 171,000,000 | $ 207,000,000 | ||||
Line of Credit Facility, Remaining Borrowing Capacity | 411,500,000 | 411,500,000 | |||||
Letters of Credit Outstanding, Amount | 2,500,000 | 2,500,000 | |||||
Line of Credit [Member] | Amended and Restated Senior Credit Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 585,000,000 | ||||||
Convertible Notes Payable [Member] | 2.625 Percent Convertible Notes Due 2024 [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Face Amount | $ 345,000,000 | ||||||
Debt Instrument, Convertible, Carrying Amount of Equity Component | $ 39,100,000 | ||||||
Amortization of debt discount | 2,600,000 | $ 2,400,000 | 7,600,000 | 7,200,000 | |||
Interest rate, stated percentage | 2.625% | ||||||
Debt Instrument, Interest Rate, Effective Percentage | 6.14% | ||||||
Interest Expense, Debt | $ 2,300,000 | $ 2,300,000 | $ 6,800,000 | $ 6,800,000 | |||
Debt Instrument, Convertible, Gross Amount of Equity Component | $ 51,600,000 | ||||||
Conversion price (in dollars per share) | $ / shares | $ 88.80 | ||||||
Debt Instrument, Convertible, Conversion Ratio | 11.2608 | ||||||
Convertible Notes Payable [Member] | 2.625 Percent Convertible Notes Due 2024 [Member] | Warrant | |||||||
Debt Instrument [Line Items] | |||||||
Option indexed to issuer's equity, strike price (in dollars per share) | $ / shares | $ 114.92 | ||||||
Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Interest Rate, Effective Percentage | 1.625% | 1.625% | |||||
LIBOR Interest Rate Floor | 0.125% | ||||||
Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Basis Spread on Variable Rate | 1.50% | ||||||
Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member] | Adjusted LIBOR | |||||||
Debt Instrument [Line Items] | |||||||
Debt Instrument, Basis Spread on Variable Rate | 1.00% | ||||||
Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member] | Fed Funds Effective Rate Overnight Index Swap Rate [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Line of Credit Facility, Commitment Fee Percentage | 0.50% | ||||||
Call Option [Member] | Convertible Notes Payable [Member] | 2.625 Percent Convertible Notes Due 2024 [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Hedge and warrant transactions, net cash paid | $ 21,000,000 |
Long Term Debt Maturities of Lo
Long Term Debt Maturities of Long Term Debt (Details) $ in Thousands | Sep. 30, 2021USD ($) |
Maturities of Long-term Debt [Abstract] | |
Remaining, 2021 | $ 2,981 |
2022 | 11,925 |
2023 | 14,906 |
2024 | 365,869 |
2025 | 23,850 |
2026 | $ 327,018 |
Guarantees (Details)
Guarantees (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Guarantees [Abstract] | ||
Standard warranty period (in years) | 1 year | |
Movement in Standard Product Warranty Accrual [Roll Forward] | ||
Balance as of January 1, | $ 1,826 | $ 2,186 |
Provision for warranties | 1,235 | 616 |
Claims made | (683) | (932) |
Balance as of September 30, | 2,378 | 1,870 |
Extended Product Warranty Disclosure [Abstract] | ||
Product extended warranty expense | $ 5,200 | $ 4,400 |
Pension Plan (Details)
Pension Plan (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Retirement Benefits [Abstract] | ||||
Service cost | $ 248 | $ 179 | $ 744 | $ 537 |
Interest cost on projected benefit obligation | 451 | 639 | 1,353 | 1,917 |
Expected return on plan assets | (1,289) | (1,255) | (3,867) | (3,765) |
Net amortization and deferral | 832 | 705 | 2,496 | 2,115 |
Net periodic pension cost | $ 242 | 268 | $ 726 | 804 |
Defined Benefit Plan, Non-service cost | $ 100 | $ 300 |
Acquisition and Other Expense_2
Acquisition and Other Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Acquisition and Other Expense [Line Items] | ||||
Other expense | $ 1,127 | $ 89 | $ 1,127 | $ 266 |
Cost of Sales | ||||
Acquisition and Other Expense [Line Items] | ||||
Plant underutilization cost | 0 | 0 | 0 | 6,586 |
Product rationalization costs - inventory | 0 | 0 | 0 | 2,169 |
Restructuring costs | 0 | 0 | 0 | 1,087 |
Manufacturing consolidation costs | 0 | 606 | 0 | 3,993 |
Acquisition and integration costs | 0 | 796 | 0 | 2,253 |
Acquisition and other expense | 0 | 1,402 | 0 | 16,088 |
Selling and Administrative Expenses | ||||
Acquisition and Other Expense [Line Items] | ||||
Restucturing and related costs | 0 | 1,009 | 414 | 3,133 |
Product rationalization costs - field inventory | 0 | 0 | 0 | 2,095 |
Acquisition and integration costs | 0 | 0 | 0 | 1,192 |
Acquisition and other expense | 0 | 1,009 | 414 | 6,420 |
Selling and Administrative Expenses | Special Termination Benefits [Member] | ||||
Acquisition and Other Expense [Line Items] | ||||
Restucturing and related costs | 800 | |||
Selling and Administrative Expenses | Contract Termination [Member] | ||||
Acquisition and Other Expense [Line Items] | ||||
Restucturing and related costs | 1,000 | 2,300 | ||
Other Expense | ||||
Acquisition and Other Expense [Line Items] | ||||
Other expense | $ 1,127 | $ 0 | $ 1,127 | $ 0 |
Business Segment (Details)
Business Segment (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Segment Reporting Information [Line Items] | ||||
Net sales | $ 248,827 | $ 237,835 | $ 736,665 | $ 609,631 |
Orthopedic Surgery | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | 105,751 | 102,187 | 320,809 | 261,954 |
General Surgery | ||||
Segment Reporting Information [Line Items] | ||||
Net sales | $ 143,076 | $ 135,648 | $ 415,856 | $ 347,677 |
Legal Proceedings (Details)
Legal Proceedings (Details) - USD ($) $ in Millions | Jan. 18, 2017 | Sep. 30, 2021 |
Loss Contingencies [Line Items] | ||
Product liability insurance, amount per incident | $ 35 | |
Product liability insurance, aggregate annual amount | $ 35 | |
Pending Litigation | EndoDynamix, Inc. | Liquidated Damages | ||
Loss Contingencies [Line Items] | ||
Loss Contingency, Damages Sought, Value | $ 12.7 | |
Pending Litigation | EndoDynamix, Inc. | Additional Damages | ||
Loss Contingencies [Line Items] | ||
Loss Contingency, Damages Sought, Value | $ 24.8 |